Editor’s Note Archive

Last June, a perceptions poll of 370 gender specialists conducted by TrustLaw, a legal news service run by Thomson Reuters…

The new rules on compensation for death/ injury during clinical trials once again highlight the tough choices faced by our policy…

'The Fourth Estate: A Watchdog or A Hound?' That was the topic of the 17th Lalit Doshi Memorial Lecture, given by Shekhar Gupta,…

Clinical trials and research in India seems to be in danger of getting mired in the quicksand of evolving regulation. And going by…

With 2013 all set to be a watershed year in the life sciences sector in India, we present some ‘Predictions from Pharma Pundits’…

Piramal Enterprises' second buy in the pharmaceutical analytics sector, the UK-based Abacus International, is an indicator of the…

The pharmaceutical industry used to be considered recession proof as compared to other sectors, but that myth has been roundly…

In my editorial dated June 29, I had asked, ‘Obamacare passed, but will Obama?’ (bit.ly/UmOwq7). 

In the run up to our 18th Anniversary issue, we ran a poll on our website, with the motion of the house being: The Indian patent…

With the Supreme Court closely tracking policy makers, both on the drug pricing and clinical trials front, will the pharmaceutical…